Fraxinellone mitigates acute lung injury by targeting HIF-1α to suppress pyroptosis and inflammation
-
By
-
Bing Zhang
-
Xiaoning Lu
-
Yuefei Zhang
-
Xinyu Shen
-
Zhongbing Tan
-
Junling Leng
-
Yifei Chen
-
Hui Shen
-
Yong Li
-
July 16, 2026
Clinical Scorecard: Fraxinellone Reduces Acute Lung Injury by Inhibiting HIF-1α, Leading to Decreased Pyroptosis and Inflammation
At a Glance
| Category | Detail |
|---|
| Condition | Acute Pulmonary Contusion (APC) |
| Key Mechanisms | Inhibition of HIF-1α, reduction of pyroptosis and inflammation |
| Target Population | Patients with acute pulmonary contusion |
| Care Setting | Critical care environments |
Key Highlights
- Fraxinellone (FRA) reduces APC severity by inhibiting HIF-1α.
- FRA decreases levels of pro-inflammatory cytokines IL-1β, IL-6, and IL-18.
- FRA mitigates pyroptosis markers NLRP3 and GSDMD.
- Mechanistic validation shows FRA's pathway specificity through HIF-1α modulation.
- FRA provides a novel therapeutic approach for trauma-induced lung injury.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of APC should consider clinical history of thoracic trauma.
Management
- Current management of APC is primarily supportive care; targeted pharmacological therapies are lacking.
Monitoring & Follow-up
- Monitor inflammatory markers and pulmonary function in patients with APC.
Risks
- APC can progress to acute respiratory distress syndrome (ARDS) if not managed appropriately.
Patient & Prescribing Data
C57BL/6 mice used in preclinical models for efficacy testing.
FRA administered at 5 mg/kg in vivo and 10 μM in vitro demonstrated significant therapeutic effects.
Clinical Best Practices
- Consider pharmacological inhibition of HIF-1α in managing APC.
- Utilize anti-inflammatory strategies to mitigate pulmonary injury.
Related Resources & Content
